G. P. Adams, J. E. Mccartney, M. Tai, H. Oppermann, J. S. Huston et al., Highly Specific in Vivo Tumor Targeting by Monovalent and Divalent Forms of 741F8 Anti-c-erbB-2 Single-Chain Fv, Cancer Res, vol.53, pp.4026-4034, 1993.

G. P. Adams, R. Schier, A. M. Mccall, H. H. Simmons, E. M. Horak et al., High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules, Cancer Res, vol.61, pp.4750-4755, 2001.

J. B. Adlersberg, The immunoglobulin hinge (interdomain) region, Ric. Clin. Lab, vol.6, pp.191-205, 1976.

N. J. Agard, J. A. Prescher, and C. R. Bertozzi, A Strain-Promoted [3 + 2] Azide?Alkyne Cycloaddition for Covalent Modification of Biomolecules in Living Systems, J. Am. Chem. Soc, vol.126, pp.15046-15047, 2004.

P. Agarwal, J. Van-der-weijden, E. M. Sletten, D. Rabuka, and C. R. Bertozzi, A Pictet-Spengler ligation for protein chemical modification, Proc. Natl. Acad. Sci. U. S. A, vol.110, pp.46-51, 2013.

P. Agarwal, R. Kudirka, A. E. Albers, R. M. Barfield, G. W. De-hart et al., Hydrazino-Pictet-Spengler ligation as a biocompatible method for the generation of stable protein conjugates, Bioconjug. Chem, vol.24, pp.846-851, 2013.

C. Alewine, R. Hassan, and I. Pastan, Advances in Anticancer Immunotoxin Therapy, vol.20, pp.176-185, 2015.

J. C. Almagro, Natural and man-made V-gene repertoires for antibody discovery, B Cell Biol, vol.3, 2012.

K. Alt, B. M. Paterson, E. Westein, S. E. Rudd, S. S. Poniger et al., A versatile approach for the sitespecific modification of recombinant antibodies using a combination of enzyme-mediated bioconjugation and click chemistry, Angew. Chem. Int. Ed Engl, vol.54, pp.7515-7519, 2015.

H. Ando, M. Adachi, K. Umeda, A. Matsuura, M. Nonaka et al., Purification and Characteristics of a Novel Transglutaminase Derived from Microorganisms, Agric. Biol. Chem, vol.53, pp.2613-2617, 1989.

J. Y. Axup, K. M. Bajjuri, M. Ritland, B. M. Hutchins, C. H. Kim et al., Synthesis of site-specific antibody-drug conjugates using unnatural amino acids, Proc. Natl. Acad. Sci, vol.109, pp.16101-16106, 2012.

L. Baldi, D. L. Hacker, M. Adam, and F. M. Wurm, Recombinant protein production by large-scale transient gene expression in mammalian cells: state of the art and future perspectives, Biotechnol. Lett, vol.29, pp.677-684, 2007.

B. A. Baldo, Adverse events to monoclonal antibodies used for cancer therapy, Oncoimmunology, vol.2, 2013.

A. D. Baldwin and K. L. Kiick, Tunable Degradation of Maleimide-Thiol Adducts in Reducing Environments, Bioconjug. Chem, vol.22, pp.1946-1953, 2011.

A. Beck, Biosimilar, biobetter and next generation therapeutic antibodies, mAbs, vol.3, pp.107-110, 2011.

A. Beck and J. M. Reichert, Marketing approval of mogamulizumab, mAbs, vol.4, pp.419-425, 2012.

O. Berteau, A. Guillot, A. Benjdia, and S. Rabot, A new type of bacterial sulfatase reveals a novel maturation pathway in prokaryotes, J. Biol. Chem, vol.281, pp.22464-22470, 2006.
URL : https://hal.archives-ouvertes.fr/hal-02656640

F. Bibeau, E. Lopez-crapez, F. Di-fiore, S. Thezenas, M. Ychou et al., Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.27, pp.1122-1129, 2009.

M. L. Blackman, M. Royzen, and J. M. Fox, Tetrazine Ligation: Fast Bioconjugation Based on Inverse-Electron-Demand Diels?Alder Reactivity, J. Am. Chem. Soc, vol.130, pp.13518-13519, 2008.

A. T. Blomquist and L. H. Liu, Many-membered Carbon Rings. VII. Cycloöctyne, J. Am. Chem. Soc, vol.75, pp.2153-2154, 1953.

M. J. Borrok, S. T. Jung, T. H. Kang, A. F. Monzingo, and G. Georgiou, Revisiting the role of glycosylation in the structure of human IgG Fc, ACS Chem. Biol, vol.7, pp.1596-1602, 2012.

P. N. Boyd, A. C. Lines, and A. K. Patel, The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H, Mol. Immunol, vol.32, pp.1311-1318, 1995.

N. J. Boylan, W. Zhou, R. J. Proos, T. J. Tolbert, J. L. Wolfe et al., , 2013.

, Conjugation Site Heterogeneity Causes Variable Electrostatic Properties in Fc Conjugates, Bioconjug. Chem, vol.24, pp.1008-1016

D. Bregeon, P. Dennler, C. Belmant, L. Gauthier, F. Romagné et al., Enzymatic Conjugation of Polypeptides, 2013.

F. Brotzel and H. Mayr, Nucleophilicities of amino acids and peptides, Org. Biomol. Chem, vol.5, pp.3814-3820, 2007.

L. Brown, J. M. Wolf, R. Prados-rosales, and A. Casadevall, Through the wall: extracellular vesicles in Gram-positive bacteria, mycobacteria and fungi, Nat. Rev. Microbiol, vol.13, pp.620-630, 2015.

F. Bryden, A. Maruani, H. Savoie, V. Chudasama, M. E. Smith et al., Regioselective and stoichiometrically controlled conjugation of photodynamic sensitizers to a HER2 targeting antibody fragment, Bioconjug. Chem, vol.25, pp.611-617, 2014.

A. Caporale, F. Selis, A. Sandomenico, G. S. Jotti, G. Tonon et al., The LQSP tetrapeptide is a new highly efficient substrate of microbial transglutaminase for the sitespecific derivatization of peptides and proteins, Biotechnol. J, vol.10, pp.154-161, 2015.

B. L. Carlson, E. R. Ballister, E. Skordalakes, D. S. King, M. A. Breidenbach et al., Function and Structure of a Prokaryotic Formylglycinegenerating Enzyme, J. Biol. Chem, vol.283, pp.20117-20125, 2008.

I. S. Carrico, B. L. Carlson, and C. R. Bertozzi, Introducing genetically encoded aldehydes into proteins, Nat. Chem. Biol, vol.3, pp.321-322, 2007.

P. Carter, Improving the efficacy of antibody-based cancer therapies, Nat. Rev. Cancer, vol.1, pp.118-129, 2001.

P. Carter, R. F. Kelley, M. L. Rodrigues, B. Snedecor, M. Covarrubias et al., High Level Escherichia coli Expression and Production of a Bivalent Humanized Antibody Fragment, Nat. Biotechnol, vol.10, pp.163-167, 1992.

G. Cartron, L. Dacheux, G. Salles, P. Solal-celigny, P. Bardos et al., Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene, Blood, vol.99, pp.754-758, 2002.

C. E. Chan, A. P. Lim, A. H. Chan, P. A. Macary, and B. J. Hanson, Optimized expression of full-length IgG1 antibody in a common E. coli strain, PloS One, vol.5, p.10261, 2010.

C. E. Chan, A. H. Chan, A. P. Lim, and B. J. Hanson, Comparison of the efficiency of antibody selection from semi-synthetic scFv and non-immune Fab phage display libraries against protein targets for rapid development of diagnostic immunoassays, J. Immunol. Methods, vol.373, pp.79-88, 2011.

C. E. Chan, A. P. Lim, P. A. Macary, and B. J. Hanson, The role of phage display in therapeutic antibody discovery, Int. Immunol, vol.26, pp.649-657, 2014.

A. P. Chapman, P. Antoniw, M. Spitali, S. West, S. Stephens et al., Therapeutic antibody fragments with prolonged in vivo half-lives, Nat. Biotechnol, vol.17, pp.780-783, 1999.

H. Cho and J. Jaworski, Enzyme directed formation of un-natural side-chains for covalent surface attachment of proteins, Colloids Surf. B Biointerfaces, vol.122, pp.846-850, 2014.

Y. Cong, E. Pawlisz, P. Bryant, S. Balan, E. Laurine et al., Site-Specific PEGylation at Histidine Tags, Bioconjug. Chem, vol.23, pp.248-263, 2012.

M. P. Cosma, S. Pepe, I. Annunziata, R. F. Newbold, M. Grompe et al., The multiple sulfatase deficiency gene encodes an essential and limiting factor for the activity of sulfatases, Cell, vol.113, pp.445-456, 2003.

A. Coulter and R. Harris, Simplified preparation of rabbit Fab fragments, J. Immunol. Methods, vol.59, pp.199-203, 1983.

W. F. Dall'acqua, K. E. Cook, M. M. Damschroder, R. M. Woods, and H. Wu, , 2006.

, Modulation of the Effector Functions of a Human IgG1 through Engineering of Its Hinge Region, J. Immunol, vol.177, pp.1129-1138

L. M. Damasceno, K. A. Anderson, G. Ritter, J. M. Cregg, L. J. Old et al., , 2006.

, Cooverexpression of chaperones for enhanced secretion of a single-chain antibody fragment in Pichia pastoris, Appl. Microbiol. Biotechnol, vol.74, pp.381-389

S. Damodaran, WO2000070026 -A novel transglutaminase from $i(Streptoverticillium mobaraens), 2000.

M. F. Debets, S. S. Berkel, . Van, S. Schoffelen, F. P. Rutjes et al., Aza-dibenzocyclooctynes for fast and efficient enzyme PEGylation via copperfree (3+2) cycloaddition, Chem. Commun, vol.46, pp.97-99, 2010.

P. Dennler, A. Chiotellis, E. Fischer, D. Brégeon, C. Belmant et al., Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody-drug conjugates, Bioconjug. Chem, vol.25, pp.569-578, 2014.

P. Dennler, L. K. Bailey, P. R. Spycher, R. Schibli, and E. Fischer, Microbial transglutaminase and c-myc-tag: a strong couple for the functionalization of antibody-like protein scaffolds from discovery platforms. Chembiochem Eur, J. Chem. Biol, vol.16, pp.861-867, 2015.

L. Detalle, T. Stohr, C. Palomo, P. A. Piedra, B. E. Gilbert et al., Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection, Antimicrob. Agents Chemother, vol.60, pp.6-13, 2015.

K. M. Dhodapkar, J. L. Kaufman, M. Ehlers, D. K. Banerjee, E. Bonvini et al., Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells, Proc. Natl. Acad. Sci. U. S. A, vol.102, pp.2910-2915, 2005.

D. Giacomo, A. M. Danielli, R. Guidoboni, M. Calabrò, L. Carlucci et al., Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases, Cancer Immunol. Immunother. CII, vol.58, pp.1297-1306, 2009.

C. A. Diebolder, F. J. Beurskens, R. N. De-jong, R. I. Koning, K. Strumane et al., Complement Is Activated by IgG Hexamers Assembled at the Cell Surface. Science, vol.343, pp.1260-1263, 2014.

T. Dierks, C. Miech, J. Hummerjohann, B. Schmidt, M. A. Kertesz et al., , 1998.

, Posttranslational Formation of Formylglycine in Prokaryotic Sulfatases by Modification of Either Cysteine or Serine, J. Biol. Chem, vol.273, pp.25560-25564

T. Dierks, B. Schmidt, L. V. Borissenko, J. Peng, A. Preusser et al., Multiple Sulfatase Deficiency Is Caused by Mutations in the Gene Encoding the Human C?-Formylglycine Generating Enzyme, Cell, vol.113, pp.435-444, 2003.

H. M. Dijstelbloem, J. G. Van-de-winkel, and C. G. Kallenberg, Inflammation in autoimmunity: receptors for IgG revisited, Trends Immunol, vol.22, pp.510-516, 2001.

D. J. Dilillo and J. V. Ravetch, Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions, Cancer Immunol. Res, vol.3, pp.704-713, 2015.

J. Dommerholt, S. Schmidt, R. Temming, L. J. Hendriks, F. P. Rutjes et al., Readily Accessible Bicyclononynes for Bioorthogonal Labeling and Three-Dimensional Imaging of Living Cells, Angew. Chem. Int. Ed, vol.49, pp.9422-9425, 2010.

P. M. Drake, A. E. Albers, J. Baker, S. Banas, R. M. Barfield et al., Aldehyde Tag Coupled with HIPS Chemistry Enables the Production of ADCs Conjugated Site-Specifically to Different Antibody Regions with Distinct in Vivo Efficacy and PK Outcomes, Bioconjug. Chem, vol.25, pp.1331-1341, 2014.

J. Dumont, D. Euwart, B. Mei, S. Estes, and R. Kshirsagar, Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives, Crit. Rev. Biotechnol, pp.1-13, 2015.

D. M. Ecker, S. D. Jones, and H. L. Levine, The therapeutic monoclonal antibody market. mAbs, vol.7, pp.9-14, 2015.

P. Eldin, M. E. Pauza, Y. Hieda, G. Lin, M. P. Murtaugh et al., High-level secretion of two antibody single chain Fv fragments by Pichia pastoris, J. Immunol. Methods, vol.201, pp.67-75, 1997.
URL : https://hal.archives-ouvertes.fr/hal-02438884

D. P. English, S. Bellone, C. L. Schwab, D. M. Roque, S. Lopez et al., Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapyresistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo, Cancer, vol.121, pp.403-412, 2015.

S. E. Farias, P. Strop, K. Delaria, M. Galindo-casas, M. Dorywalska et al., Mass Spectrometric Characterization of Transglutaminase Based Site-Specific Antibody-Drug Conjugates, Bioconjug. Chem, vol.25, pp.240-250, 2014.

M. J. Feige, S. Nath, S. R. Catharino, D. Weinfurtner, S. Steinbacher et al., Structure of the murine unglycosylated IgG1 Fc fragment, J. Mol. Biol, vol.391, pp.599-608, 2009.

K. Von-figura, B. Schmidt, T. Selmer, and T. Dierks, A novel protein modification generating an aldehyde group in sulfatases: its role in catalysis and disease, BioEssays News Rev. Mol. Cell. Dev. Biol, vol.20, pp.505-510, 1998.

D. Filpula, Antibody engineering and modification technologies, Biomol. Eng, vol.24, pp.201-215, 2007.

S. D. Fontaine, R. Reid, L. Robinson, G. W. Ashley, and D. V. Santi, Long-term stabilization of maleimide-thiol conjugates, Bioconjug. Chem, vol.26, pp.145-152, 2015.

A. Fontana, B. Spolaore, A. Mero, and F. M. Veronese, Site-specific modification and PEGylation of pharmaceutical proteins mediated by transglutaminase, Adv. Drug Deliv. Rev, vol.60, pp.13-28, 2008.

A. Forero-torres, S. De-vos, B. L. Pohlman, M. Pashkevich, D. M. Cronier et al., Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in Fc?RIIIa-genotyped patients with previously treated follicular lymphoma, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, vol.18, pp.1395-1403, 2012.

A. Frenzel, M. Hust, and T. Schirrmann, Expression of recombinant antibodies, Front. Immunol, vol.4, p.217, 2013.

N. Gaborit, C. Larbouret, J. Vallaghe, F. Peyrusson, C. Bascoul-mollevi et al., Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies, J. Biol. Chem, vol.286, pp.11337-11345, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00576598

B. Gasser, M. Maurer, J. Gach, R. Kunert, and D. Mattanovich, Engineering of Pichia pastoris for improved production of antibody fragments, Biotechnol. Bioeng, vol.94, pp.353-361, 2006.

C. L. Gaughan, The present state of the art in expression, production and characterization of monoclonal antibodies, Mol. Divers, 2015.

C. A. Gerdes, V. G. Nicolini, S. Herter, E. Van-puijenbroek, S. Lang et al., GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, vol.19, pp.1126-1138, 2013.

C. Germain, E. Campigna, I. Salhi, S. Morisseau, I. Navarro-teulon et al., Redirecting NK cells mediated tumor cell lysis by a new recombinant bifunctional protein, Protein Eng. Des. Sel, vol.21, pp.665-672, 2008.
URL : https://hal.archives-ouvertes.fr/inserm-00325786

V. Ghetie, J. G. Hubbard, J. K. Kim, M. F. Tsen, Y. Lee et al., Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice, Eur. J. Immunol, vol.26, pp.690-696, 1996.

J. M. Gilmore, R. A. Scheck, A. P. Esser-kahn, N. S. Joshi, and M. B. Francis, N-Terminal Protein Modification through a Biomimetic Transamination Reaction, Angew. Chem. Int. Ed, vol.45, pp.5307-5311, 2006.

V. Goede, K. Fischer, R. Busch, A. Engelke, B. Eichhorst et al., Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions, N. Engl. J. Med, vol.370, pp.1101-1110, 2014.

C. P. Graff, K. Chester, R. Begent, and K. D. Wittrup, Directed evolution of an anticarcinoembryonic antigen scFv with a 4-day monovalent dissociation half-time at 37 degrees C, Protein Eng. Des. Sel. PEDS, vol.17, pp.293-304, 2004.

L. L. Green, M. C. Hardy, C. E. Maynard-currie, H. Tsuda, D. M. Louie et al., Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs, Nat. Genet, vol.7, pp.13-21, 1994.

A. Grevys, M. Bern, S. Foss, D. B. Bratlie, A. Moen et al., Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions, J. Immunol. Baltim. Md, pp.5497-5508, 2015.

N. Griebenow, A. M. Dilmaç, S. Greven, and S. Bräse, Site-Specific Conjugation of Peptides and Proteins via Rebridging of Disulfide Bonds Using the Thiol-Yne Coupling Reaction, Bioconjug. Chem, vol.27, pp.911-917, 2016.

R. J. Griffin, The medicinal chemistry of the azido group, Prog. Med. Chem, vol.31, pp.121-232, 1994.

L. S. Grinna and J. F. Tschopp, Size distribution and general structural features of Nlinked oligosaccharides from the methylotrophic yeast, Pichia pastoris. Yeast, vol.5, pp.107-115, 1989.

M. T. Gundersen, J. W. Keillor, and J. N. Pelletier, Microbial transglutaminase displays broad acyl-acceptor substrate specificity, Appl. Microbiol. Biotechnol, vol.98, pp.219-230, 2014.

C. Gurkan, S. N. Symeonides, and D. J. Ellar, High-level production in Pichia pastoris of an anti-p185HER-2 single-chain antibody fragment using an alternative secretion expression vector, Biotechnol. Appl. Biochem, vol.39, pp.115-122, 2004.

S. R. Hamilton, P. Bobrowicz, B. Bobrowicz, R. C. Davidson, H. Li et al., Production of Complex Human Glycoproteins in Yeast, Science, vol.301, pp.1244-1246, 2003.

S. R. Hamilton, R. C. Davidson, N. Sethuraman, J. H. Nett, Y. Jiang et al., Humanization of yeast to produce complex terminally sialylated glycoproteins, Science, vol.313, pp.1441-1443, 2006.

F. A. Harding, M. M. Stickler, J. Razo, and R. B. Dubridge, The immunogenicity of humanized and fully human antibodies, vol.2, pp.256-265, 2010.

S. B. Hassan, J. F. Sørensen, B. N. Olsen, and A. E. Pedersen, Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials, Immunopharmacol. Immunotoxicol, vol.36, pp.96-104, 2014.

K. Heider, K. Kiefer, T. Zenz, M. Volden, S. Stilgenbauer et al., A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies, Blood, vol.118, pp.4159-4168, 2011.

L. M. Henricks, J. H. Schellens, A. D. Huitema, and J. H. Beijnen, The use of combinations of monoclonal antibodies in clinical oncology, Cancer Treat. Rev, vol.41, pp.859-867, 2015.

F. Higel, A. Seidl, F. Sörgel, and W. Friess, N-glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and Fc fusion proteins, Eur. J. Pharm. Biopharm, vol.100, pp.94-100, 2016.

K. Hilpert, G. Hansen, H. Wessner, G. Küttner, K. Welfle et al., , 2001.

, Anti-c-myc antibody 9E10: epitope key positions and variability characterized using peptide spot synthesis on cellulose, Protein Eng, vol.14, pp.803-806

P. R. Hinton, M. G. Johlfs, J. M. Xiong, K. Hanestad, K. C. Ong et al., Engineered human IgG antibodies with longer serum half-lives in primates, J. Biol. Chem, vol.279, pp.6213-6216, 2004.

P. R. Hinton, J. M. Xiong, M. G. Johlfs, M. T. Tang, S. Keller et al., An engineered human IgG1 antibody with longer serum half-life, J. Immunol. Baltim. Md, vol.176, pp.346-356, 1950.

J. Hodoniczky, Y. Z. Zheng, J. , and D. C. , Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro, Biotechnol. Prog, vol.21, pp.1644-1652, 2005.

V. Hong, N. F. Steinmetz, M. Manchester, and M. G. Finn, Labeling Live Cells by Copper-Catalyzed Alkyne?Azide Click Chemistry, Bioconjug. Chem, vol.21, pp.1912-1916, 2010.

H. R. Hoogenboom, Selecting and screening recombinant antibody libraries, Nat. Biotechnol, vol.23, pp.1105-1116, 2005.

M. Hosono, K. Endo, H. Sakahara, Y. Watanabe, T. Saga et al., Human/mouse chimeric antibodies show low reactivity with human anti-murine antibodies (HAMA), Br. J. Cancer, vol.65, pp.197-200, 1992.

J. E. Hudak, H. H. Yu, and C. R. Bertozzi, Protein Glycoengineering Enabled by the Versatile Synthesis of Aminooxy Glycans and the Genetically Encoded Aldehyde Tag, J. Am. Chem. Soc, vol.133, pp.16127-16135, 2011.

J. E. Hudak, R. M. Barfield, G. W. De-hart, P. Grob, E. Nogales et al., Synthesis of Heterobifunctional Protein Fusions Using Copper-Free Click Chemistry and the Aldehyde Tag, Angew. Chem. Int. Ed, vol.51, pp.4161-4165, 2012.

C. A. Hudis, Trastuzumab -Mechanism of Action and Use in Clinical Practice, N. Engl. J. Med, vol.357, pp.39-51, 2007.

R. Huisgen, 1,3-Dipolar Cycloadditions. Past and Future, Angew. Chem. Int. Ed. Engl, vol.2, pp.565-598, 1963.

E. E. Idusogie, P. Y. Wong, L. G. Presta, H. Gazzano-santoro, K. Totpal et al., Engineered Antibodies with Increased Activity to Recruit Complement, J. Immunol, vol.166, pp.2571-2575, 2001.

S. Jeger, Site-specific conjugation of tumour-targeting, antibodies using transglutaminase, 2009.

S. Jeger, K. Zimmermann, A. Blanc, J. Grünberg, M. Honer et al., Site-Specific and Stoichiometric Modification of Antibodies by Bacterial Transglutaminase, Angew. Chem. Int. Ed, vol.49, pp.9995-9997, 2010.

P. T. Jones, P. H. Dear, J. Foote, M. S. Neuberger, and G. Winter, Replacing the complementarity-determining regions in a human antibody with those from a mouse, Nature, vol.321, pp.522-525, 1986.

R. N. Jong, . De, F. J. Beurskens, S. Verploegen, K. Strumane et al., A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface, PLOS Biol, vol.14, 2016.

A. Josten, L. Haalck, F. Spener, and M. Meusel, Use of microbial transglutaminase for the enzymatic biotinylation of antibodies, J. Immunol. Methods, vol.240, pp.47-54, 2000.

T. T. Junttila, K. Parsons, C. Olsson, Y. Lu, Y. Xin et al., Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer, Cancer Res, vol.70, pp.4481-4489, 2010.

J. R. Junutula, H. Raab, S. Clark, S. Bhakta, D. D. Leipold et al., Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index, Nat. Biotechnol, vol.26, pp.925-932, 2008.

J. R. Junutula, S. Bhakta, H. Raab, K. E. Ervin, C. Eigenbrot et al., Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs, J. Immunol. Methods, vol.332, pp.41-52, 2008.

J. R. Junutula, K. M. Flagella, R. A. Graham, K. L. Parsons, E. Ha et al., Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer, Clin. Cancer Res, vol.16, pp.4769-4778, 2010.

J. Kalia and R. T. Raines, Hydrolytic Stability of Hydrazones and Oximes, Angew. Chem. Int. Ed, vol.47, pp.7523-7526, 2008.

T. Kanaji, H. Ozaki, T. Takao, H. Kawajiri, H. Ide et al., Primary structure of microbial transglutaminase from Streptoverticillium sp. strain s-8112, J. Biol. Chem, vol.268, pp.11565-11572, 1993.

T. Kashiwagi, K. Yokoyama, K. Ishikawa, K. Ono, D. Ejima et al., Crystal structure of microbial transglutaminase from Streptoverticillium mobaraense, J. Biol. Chem, vol.277, pp.44252-44260, 2002.

P. Kele, X. Li, M. Link, K. Nagy, A. Herner et al., , 2009.

, Clickable fluorophores for biological labeling--with or without copper, Org. Biomol. Chem, vol.7, pp.3486-3490

H. Khalili, A. Godwin, J. Choi, R. Lever, and S. Brocchini, Comparative Binding of Disulfide-Bridged PEG-Fabs, Bioconjug. Chem, vol.23, pp.2262-2277, 2012.

J. Y. Kim, Y. Kim, and G. M. Lee, CHO cells in biotechnology for production of recombinant proteins: current state and further potential, Appl. Microbiol. Biotechnol, vol.93, pp.917-930, 2011.

M. T. Kim, Y. Chen, J. Marhoul, and F. Jacobson, Statistical modeling of the drug load distribution on trastuzumab emtansine (Kadcyla), a lysine-linked antibody drug conjugate, Bioconjug. Chem, vol.25, pp.1223-1232, 2014.

M. King and A. Wagner, Developments in the Field of Bioorthogonal Bond Forming Reactions-Past and Present Trends, Bioconjug. Chem, vol.25, pp.825-839, 2014.

S. M. Kipriyanov, G. Moldenhauer, and M. Little, High level production of soluble single chain antibodies in small-scale Escherichia coli cultures, J. Immunol. Methods, vol.200, pp.69-77, 1997.

A. Knappik, L. Ge, A. Honegger, P. Pack, M. Fischer et al., Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides, J. Mol. Biol, vol.296, pp.57-86, 2000.

J. T. Koerber, M. J. Hornsby, and J. A. Wells, An improved single-chain fab platform for efficient display and recombinant expression, J. Mol. Biol, vol.427, pp.576-586, 2015.

G. Köhler and C. Milstein, Continuous cultures of fused cells secreting antibody of predefined specificity, Nature, vol.256, pp.495-497, 1975.

H. C. Kolb, M. G. Finn, and K. B. Sharpless, Click Chemistry: Diverse Chemical Function from a Few Good Reactions, Angew. Chem. Int. Ed Engl, vol.40, 2001.

O. Koniev and A. Wagner, Developments and recent advancements in the field of endogenous amino acid selective bond forming reactions for bioconjugation, Chem. Soc. Rev, vol.44, pp.5495-5551, 2015.

O. Koniev, G. Leriche, M. Nothisen, J. Remy, J. Strub et al., Selective Irreversible Chemical Tagging of Cysteine with 3-Arylpropiolonitriles, Bioconjug. Chem, vol.25, pp.202-206, 2014.
URL : https://hal.archives-ouvertes.fr/hal-02475604

J. De-kruif, E. Boel, and T. Logtenberg, Selection and application of human single chain Fv antibody fragments from a semi-synthetic phage antibody display library with designed CDR3 regions, J. Mol. Biol, vol.248, pp.97-105, 1995.

S. Kubetzko, E. Balic, R. Waibel, U. Zangemeister-wittke, and A. Plückthun, , 2006.

, PEGylation and Multimerization of the Anti-p185HER-2 Single Chain Fv Fragment 4D5 EFFECTS ON TUMOR TARGETING, J. Biol. Chem, vol.281, pp.35186-35201

A. Kumar, K. A. Blum, H. C. Fung, M. R. Smith, P. A. Foster et al., A phase 1 dose-escalation study of XmAb®2513 in patients with relapsed or refractory Hodgkin lymphoma, Br. J. Haematol, vol.168, pp.902-904, 2015.

R. Kunert and D. Reinhart, Advances in recombinant antibody manufacturing, Appl. Microbiol. Biotechnol, vol.100, pp.3451-3461, 2016.

A. Kuzmin, A. Poloukhtine, M. A. Wolfert, and V. V. Popik, Surface Functionalization Using Catalyst-Free Azide?Alkyne Cycloaddition, Bioconjug. Chem, vol.21, pp.2076-2085, 2010.

E. Kwak and J. Jaworski, Controlled surface immobilization of viruses via sitespecific enzymatic modification, J. Mater. Chem. B, vol.1, pp.3486-3493, 2013.

G. A. Lazar, A. J. Chirino, W. Dang, J. R. Desjarlais, S. K. Doberstein et al., United States Patent: 7662925 -Optimized Fc variants and methods for their generation, 2010.

E. M. Lee, D. Yee, S. J. Busfield, J. F. Mcmanus, N. Cummings et al., Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice, Haematologica, vol.100, pp.914-926, 2015.

J. Lee, C. Song, D. Kim, I. Park, S. Lee et al., , 2013.

, Glutamine (Q)-peptide screening for transglutaminase reaction using mRNA display, Biotechnol. Bioeng, vol.110, pp.353-362

K. Leung, S. Batey, R. Rowlands, S. J. Isaac, P. Jones et al., A HER2-specific Modified Fc Fragment (Fcab) Induces Antitumor Effects Through Degradation of HER2 and Apoptosis, Mol. Ther, vol.23, pp.1722-1733, 2015.

F. Lhospice, D. Brégeon, C. Belmant, P. Dennler, A. Chiotellis et al., Site-Specific Conjugation of Monomethyl Auristatin E to Anti-CD30 Antibodies Improves Their Pharmacokinetics and Therapeutic Index in Rodent Models, Mol. Pharm, 2015.

J. Li, C. Zhang, T. Jostock, and S. Dübel, Analysis of IgG heavy chain to light chain ratio with mutant Encephalomyocarditis virus internal ribosome entry site, Protein Eng. Des. Sel, vol.20, pp.491-496, 2007.

S. Li, K. R. Schmitz, P. D. Jeffrey, J. J. Wiltzius, P. Kussie et al., , 2005.

S. I. Liang, J. M. Mcfarland, D. Rabuka, and Z. J. Gartner, A modular approach for assembling aldehyde-tagged proteins on DNA scaffolds, J. Am. Chem. Soc, vol.136, pp.10850-10853, 2014.

S. Liebscher, P. Kornberger, G. Fink, E. Trost-gross, E. Höss et al., Derivatization of antibody fab fragments: a designer enzyme for native protein modification. Chembiochem Eur, J. Chem. Biol, vol.15, pp.1096-1100, 2014.

R. K. Lim, L. , and Q. , Photoinducible bioorthogonal chemistry: a spatiotemporally controllable tool to visualize and perturb proteins in live cells, Acc. Chem. Res, vol.44, pp.828-839, 2011.

D. Lipovsek and A. Plückthun, In-vitro protein evolution by ribosome display and mRNA display, J. Immunol. Methods, vol.290, pp.51-67, 2004.

H. Liu, G. Bulseco, and J. Sun, Effect of posttranslational modifications on the thermal stability of a recombinant monoclonal antibody, Immunol. Lett, vol.106, pp.144-153, 2006.

H. Liu, G. Ponniah, H. Zhang, C. Nowak, A. Neill et al., In vitro and in vivo modifications of recombinant and human IgG antibodies, vol.6, pp.1145-1154, 2014.

J. Liu, D. Wei, F. Qian, Y. Zhou, J. Wang et al., pPIC9-Fc: A Vector System for the Production of Single-Chain Fv-Fc Fusions in Pichia pastoris as Detection Reagents In Vitro, J. Biochem. (Tokyo), vol.134, pp.911-917, 2003.

S. D. Liu, C. Chalouni, J. C. Young, T. T. Junttila, M. X. Sliwkowski et al., , 2015.

, Afucosylated antibodies increase activation of Fc?RIIIa-dependent signaling components to intensify processes promoting ADCC, Cancer Immunol. Res, vol.3, pp.173-183

X. Liu, L. M. Pop, and E. S. Vitetta, Engineering therapeutic monoclonal antibodies, Immunol. Rev, vol.222, pp.9-27, 2008.

Z. Liu, K. Gunasekaran, W. Wang, V. Razinkov, L. Sekirov et al., Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies, J. Biol. Chem, vol.289, pp.3571-3590, 2014.

C. Lizak, Y. Fan, T. C. Weber, A. , and M. , N-Linked Glycosylation of Antibody Fragments in Escherichia coli, Bioconjug. Chem, vol.22, pp.488-496, 2011.

N. Lonberg, L. D. Taylor, F. A. Harding, M. Trounstine, K. M. Higgins et al., Antigen-specific human antibodies from mice comprising four distinct genetic modifications, Nature, vol.368, pp.856-859, 1994.

A. Lyons, D. J. King, R. J. Owens, G. T. Yarranton, A. Millican et al.,

, Site-specific attachment to recombinant antibodies via introduced surface cysteine residues, Protein Eng, vol.3, pp.703-708

P. Martineau and J. M. Betton, In vitro folding and thermodynamic stability of an antibody fragment selected in vivo for high expression levels in Escherichia coli cytoplasm, J. Mol. Biol, vol.292, pp.921-929, 1999.

P. Martineau, P. Jones, and G. Winter, Expression of an antibody fragment at high levels in the bacterial cytoplasm, J. Mol. Biol, vol.280, pp.117-127, 1998.

K. Masuda, T. Kubota, E. Kaneko, S. Iida, M. Wakitani et al., Enhanced binding affinity for FcgammaRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity, Mol. Immunol, vol.44, pp.3122-3131, 2007.

J. Mateo, J. Berlin, J. S. Bono, . De, R. B. Cohen et al., A first-in-human study of the anti-?5?1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors, Cancer Chemother. Pharmacol, vol.74, pp.1039-1046, 2014.

C. S. Mckay and M. G. Finn, Click Chemistry in Complex Mixtures: Bioorthogonal Bioconjugation, Chem. Biol, vol.21, pp.1075-1101, 2014.

G. Y. Melmed, S. R. Targan, U. Yasothan, D. Hanicq, and P. Kirkpatrick, , 2008.

, Certolizumab pegol, Nat. Rev. Drug Discov, vol.7, pp.641-642

A. Mero, B. Spolaore, F. M. Veronese, and A. Fontana, Transglutaminase-mediated PEGylation of proteins: direct identification of the sites of protein modification by mass spectrometry using a novel monodisperse PEG, Bioconjug. Chem, vol.20, pp.384-389, 2009.

J. Messens and J. Collet, Pathways of disulfide bond formation in Escherichia coli, Int. J. Biochem. Cell Biol, vol.38, pp.1050-1062, 2006.

A. Michael, Ueber die Einwirkung von Diazobenzolimid auf Acetylendicarbonsäuremethylester, J. Für Prakt. Chem, vol.48, pp.94-95, 1893.

S. W. Michnick and S. S. Sidhu, Submitting antibodies to binding arbitration, Nat. Chem. Biol, vol.4, pp.326-329, 2008.

T. L. Mindt, V. Jungi, S. Wyss, A. Friedli, G. Pla et al., Modification of Different IgG1 Antibodies via Glutamine and Lysine using Bacterial and Human Tissue Transglutaminase, Bioconjug. Chem, vol.19, pp.271-278, 2008.

S. Möhlmann, P. Bringmann, S. Greven, and A. Harrenga, Site-specific modification of ED-B-targeting antibody using intein-fusion technology, BMC Biotechnol, vol.11, p.76, 2011.

G. Molineux and A. Newland, Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside, Br. J. Haematol, vol.150, pp.9-20, 2010.

G. L. Moore, H. Chen, S. Karki, A. , and G. , Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions, vol.2, pp.181-189, 2010.

S. L. Morrison, M. J. Johnson, L. A. Herzenberg, and V. T. Oi, Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains, Proc. Natl. Acad. Sci. U. S. A, vol.81, pp.6851-6855, 1984.

E. Mössner, P. Brünker, S. Moser, U. Püntener, C. Schmidt et al., Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity, Blood, vol.115, pp.4393-4402, 2010.

S. Moutel, A. El-marjou, O. Vielemeyer, C. Nizak, P. Benaroch et al., A multi-Fc-species system for recombinant antibody production, BMC Biotechnol, vol.9, p.14, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00565195

A. Musolino, N. Naldi, B. Bortesi, D. Pezzuolo, M. Capelletti et al., Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neupositive metastatic breast cancer, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.26, pp.1789-1796, 2008.

S. Muyldermans, Single domain camel antibodies: current status, Rev. Mol. Biotechnol, vol.74, pp.277-302, 2001.

A. Nadkarni, L. C. Kelley, and C. Momany, Optimization of a mouse recombinant antibody fragment for efficient production from Escherichia coli, Protein Expr. Purif, vol.52, pp.219-229, 2007.

A. Natarajan, W. Du, C. Xiong, G. L. Denardo, S. J. Denardo et al., Construction of di-scFv through a trivalent alkyne-azide 1,3-dipolar cycloaddition, Chem. Commun. Camb. Engl, pp.695-697, 2007.

V. D. Nguyen, F. Hatahet, K. E. Salo, E. Enlund, C. Zhang et al., , 2011.

, Pre-expression of a sulfhydryl oxidase significantly increases the yields of eukaryotic disulfide bond containing proteins expressed in the cytoplasm of, E.coli. Microb. Cell Factories, vol.10

U. Nielsen, A. Huhalov, B. Harms, V. Paragas, S. Adams et al., MM-111: a novel bispecific antibody targeting ErbB3 with potent anti-tumor activity in ErbB2 over-expressing malignancies, Cancer Res, vol.69, p.4166, 2009.

F. Nimmerjahn, S. Gordan, and A. Lux, Fc?R dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities, Trends Immunol, vol.36, pp.325-336, 2015.

R. Niwa, S. Hatanaka, E. Shoji-hosaka, M. Sakurada, Y. Kobayashi et al., Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, vol.10, pp.6248-6255, 2004.

J. L. Nordstrom, S. Gorlatov, W. Zhang, Y. Yang, L. Huang et al., Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fc? receptor binding properties, Breast Cancer Res. BCR, vol.13, p.123, 2011.

G. J. Nossal and J. Lederberg, Antibody Production by Single Cells, Nature, vol.181, pp.1419-1420, 1958.

A. Noto, C. De-vitis, G. Roscilli, L. Fattore, D. Malpicci et al., Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits non-small cell lung cancer, Oncotarget, vol.4, pp.1253-1265, 2013.

J. Novotný, R. Bruccoleri, J. Newell, D. Murphy, E. Haber et al., Molecular anatomy of the antibody binding site, J. Biol. Chem, vol.258, pp.14433-14437, 1983.

R. J. Ober, C. G. Radu, V. Ghetie, and E. S. Ward, Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies, Int. Immunol, vol.13, pp.1551-1559, 2001.

T. Ohtsuka, Y. Umezawa, N. Nio, and K. Kubota, Comparison of Deamidation Activity of Transglutaminases, J. Food Sci, vol.66, pp.25-29, 2001.

M. J. Osborn, J. E. Gander, E. Parisi, C. , and J. , Mechanism of Assembly of the Outer Membrane of Salmonella typhimurium ISOLATION AND CHARACTERIZATION OF CYTOPLASMIC AND OUTER MEMBRANE, J. Biol. Chem, vol.247, pp.3962-3972, 1972.

M. Ota, A. Sawa, N. Nio, A. , and Y. , Enzymatic ligation for synthesis of singlechain analogue of monellin by transglutaminase, Biopolymers, vol.50, pp.193-200, 1999.

K. N. Parameswaran, X. Cheng, E. C. Chen, P. T. Velasco, J. H. Wilson et al., Hydrolysis of ?:? Isopeptides by Cytosolic Transglutaminases and by Coagulation Factor XIIIa, J. Biol. Chem, vol.272, pp.10311-10317, 1997.

R. Pasternack, H. P. Laurent, T. Rüth, A. Kaiser, N. Schön et al., A fluorescent substrate of transglutaminase for detection and characterization of glutamine acceptor compounds, Anal. Biochem, vol.249, pp.54-60, 1997.

D. Patel, R. Bassi, A. Hooper, M. Prewett, D. J. Hicklin et al., Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation, Int. J. Oncol, vol.34, pp.25-32, 2009.

S. B. Petkova, S. Akilesh, T. J. Sproule, G. J. Christianson, H. Khabbaz et al., Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease, Int. Immunol, vol.18, pp.1759-1769, 2006.

P. Philibert, A. Stoessel, W. Wang, A. Sibler, N. Bec et al., A focused antibody library for selecting scFvs expressed at high levels in the cytoplasm, BMC Biotechnol, vol.7, p.81, 2007.
URL : https://hal.archives-ouvertes.fr/inserm-00192411

G. D. Phillips, G. Li, D. L. Dugger, L. M. Crocker, K. L. Parsons et al., Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate, Cancer Res, vol.68, pp.9280-9290, 2008.

I. Plagmann, A. Chalaris, A. A. Kruglov, S. Nedospasov, P. Rosenstiel et al., Transglutaminase-catalyzed covalent multimerization of camelidae antihuman TNF single domain antibodies improves neutralizing activity, J. Biotechnol, vol.142, pp.170-178, 2009.

T. I. Potgieter, S. D. Kersey, M. R. Mallem, A. C. Nylen, and M. Anjou, Antibody expression kinetics in glycoengineered Pichia pastoris, Biotechnol. Bioeng, vol.106, pp.918-927, 2010.

J. A. Prescher, D. H. Dube, and C. R. Bertozzi, Chemical remodelling of cell surfaces in living animals, Nature, vol.430, pp.873-877, 2004.

W. A. Prinz, F. Aslund, A. Holmgren, and J. Beckwith, The role of the thioredoxin and glutaredoxin pathways in reducing protein disulfide bonds in the Escherichia coli cytoplasm, J. Biol. Chem, vol.272, pp.15661-15667, 1997.

S. Puthenveetil, S. Musto, F. Loganzo, L. N. Tumey, C. J. O'donnell et al., Development of Solid-Phase Site-Specific Conjugation and Its Application toward Generation of Dual Labeled Antibody and Fab Drug Conjugates, Bioconjug. Chem, vol.27, pp.1030-1039, 2016.

G. A. Rabinovich, D. Gabrilovich, and E. M. Sotomayor, Immunosuppressive strategies that are mediated by tumor cells, Annu. Rev. Immunol, vol.25, pp.267-296, 2007.

T. S. Raju, Terminal sugars of Fc glycans influence antibody effector functions of IgGs, Curr. Opin. Immunol, vol.20, pp.471-478, 2008.

T. S. Raju, Impact of Fc Glycosylation on Monoclonal Antibody Effector Functions and Degradation by Proteases, Current Trends in Monoclonal Antibody Development and Manufacturing, pp.249-269, 2010.

P. A. Ramsland, W. Farrugia, T. M. Bradford, C. T. Sardjono, S. Esparon et al., Structural basis for Fc gammaRIIa recognition of human IgG and formation of inflammatory signaling complexes, J. Immunol. Baltim. Md, vol.187, pp.3208-3217, 1950.

Y. Reiter, U. Brinkmann, K. O. Webber, S. H. Jung, B. Lee et al., , 1994.

, Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfidestabilized Fv, Protein Eng, vol.7, pp.697-704

L. Renaut, C. Monnet, O. Dubreuil, O. Zaki, F. Crozet et al., Affinity maturation of antibodies: optimized methods to generate highquality ScFv libraries and isolate IgG candidates by high-throughput screening, Methods Mol. Biol. Clifton NJ, vol.907, pp.451-461, 2012.

L. Reslan, S. Dalle, and C. Dumontet, Understanding and circumventing resistance to anticancer monoclonal antibodies, mAbs, vol.1, pp.222-229, 2009.

J. O. Richards, S. Karki, G. A. Lazar, H. Chen, W. Dang et al., Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells, Mol. Cancer Ther, vol.7, pp.2517-2527, 2008.

T. Rispens, P. Ooijevaar-de-heer, O. Bende, A. , and R. C. , Mechanism of immunoglobulin G4 Fab-arm exchange, J. Am. Chem. Soc, vol.133, pp.10302-10311, 2011.

R. Costa, A. Elisa-rodrigues, M. Henriques, M. Azeredo, J. Oliveira et al., Guidelines to cell engineering for monoclonal antibody production, Eur. J. Pharm. Biopharm. Off. J. Arbeitsgemeinschaft Für Pharm. Verfahrenstechnik EV, vol.74, pp.127-138, 2010.

D. Ritz, J. Lim, C. M. Reynolds, L. B. Poole, and J. Beckwith, Conversion of a peroxiredoxin into a disulfide reductase by a triplet repeat expansion, Science, vol.294, pp.158-160, 2001.

G. J. Robbie, R. Criste, W. F. Dall'acqua, K. Jensen, N. K. Patel et al., A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults, Antimicrob. Agents Chemother, vol.57, pp.6147-6153, 2013.

M. Robinson, N. Ke, J. Lobstein, C. Peterson, A. Szkodny et al., Efficient expression of full-length antibodies in the cytoplasm of engineered bacteria, Nat. Commun, vol.6, p.8072, 2015.

M. A. Roguska, J. T. Pedersen, C. A. Keddy, A. H. Henry, S. J. Searle et al., Humanization of murine monoclonal antibodies through variable domain resurfacing, Proc. Natl. Acad. Sci. U. S. A, vol.91, pp.969-973, 1994.

V. V. Rostovtsev, L. G. Green, V. V. Fokin, and K. B. Sharpless, A Stepwise Huisgen Cycloaddition Process: Copper(I)-Catalyzed Regioselective "Ligation" of Azides and Terminal Alkynes, Angew. Chem. Int. Ed, vol.41, pp.2596-2599, 2002.

S. I. Rudnick, J. Lou, C. C. Shaller, Y. Tang, A. J. Klein-szanto et al., Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors, Cancer Res, vol.71, pp.2250-2259, 2011.

J. S. Rush and C. R. Bertozzi, New Aldehyde Tag Sequences Identified by Screening Formylglycine Generating Enzymes in Vitro and in Vivo, J. Am. Chem. Soc, vol.130, pp.12240-12241, 2008.

E. Saxon and C. R. Bertozzi, Cell surface engineering by a modified Staudinger reaction, Science, vol.287, pp.2007-2010, 2000.

E. Saxon, J. I. Armstrong, and C. R. Bertozzi, A "Traceless" Staudinger Ligation for the Chemoselective Synthesis of Amide Bonds, Org. Lett, vol.2, pp.2141-2143, 2000.

S. L. Sazinsky, R. G. Ott, N. W. Silver, B. Tidor, J. V. Ravetch et al., , 2008.

, Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors, Proc. Natl. Acad. Sci. U. S. A, vol.105, pp.20167-20172

B. J. Scallon, S. H. Tam, S. G. Mccarthy, A. N. Cai, and T. S. Raju, Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality, Mol. Immunol, vol.44, pp.1524-1534, 2007.

R. A. Scheck, M. T. Dedeo, A. T. Iavarone, and M. B. Francis, Optimization of a Biomimetic Transamination Reaction, J. Am. Chem. Soc, vol.130, pp.11762-11770, 2008.

M. Schlapschy, H. Gruber, O. Gresch, C. Schäfer, C. Renner et al., Functional humanization of an anti-CD30 Fab fragment for the immunotherapy of Hodgkin's lymphoma using an in vitro evolution approach, Protein Eng. Des. Sel. PEDS, vol.17, pp.847-860, 2004.

B. Schmidt, T. Selmer, A. Ingendoh, K. Figurat, and . Von, A novel amino acid modification in sulfatases that is defective in multiple sulfatase deficiency, Cell, vol.82, pp.271-278, 1995.

R. W. Schroff, K. A. Foon, S. M. Beatty, R. K. Oldham, and A. C. Morgan, Human Anti-Murine Immunoglobulin Responses in Patients Receiving Monoclonal Antibody Therapy, Cancer Res, vol.45, pp.879-885, 1985.

D. Schumacher, C. P. Hackenberger, H. Leonhardt, and J. Helma, Current Status: Site-Specific Antibody Drug Conjugates, J. Clin. Immunol, vol.36, issue.1, pp.100-107, 2016.

F. F. Schumacher, J. P. Nunes, A. Maruani, V. Chudasama, M. E. Smith et al., Next generation maleimides enable the controlled assembly of antibody-drug conjugates via native disulfide bond bridging, Org. Biomol. Chem, vol.12, pp.7261-7269, 2014.

F. Schwarz, W. Huang, C. Li, B. L. Schulz, C. Lizak et al., A combined method for producing homogeneous glycoproteins with eukaryotic N-glycosylation, Nat. Chem. Biol, vol.6, pp.264-266, 2010.

A. M. Scott, J. D. Wolchok, and L. J. Old, Antibody therapy of cancer, Nat. Rev. Cancer, vol.12, pp.278-287, 2012.

F. Selis, G. Focà, A. Sandomenico, C. Marra, C. Di-mauro et al., Pegylated Trastuzumab Fragments Acquire an Increased in Vivo Stability but Show a Largely Reduced Affinity for the Target Antigen, Int. J. Mol. Sci, vol.17, 2016.

G. Sezonov, D. Joseleau-petit, and R. Ari, Escherichia coli physiology in Luria-Bertani broth, J. Bacteriol, vol.189, pp.8746-8749, 2007.
URL : https://hal.archives-ouvertes.fr/hal-00184125

B. Shen, K. Xu, L. Liu, H. Raab, S. Bhakta et al., Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates, Nat. Biotechnol, vol.30, pp.184-189, 2012.

X. Shi, Y. Jung, L. Lin, C. Liu, C. Wu et al., Quantitative fluorescence labeling of aldehyde-tagged proteins for single-molecule imaging, Nat. Methods, vol.9, pp.499-503, 2012.

R. L. Shields, A. K. Namenuk, K. Hong, Y. G. Meng, J. Rae et al., High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R, J. Biol. Chem, vol.276, pp.6591-6604, 2001.

V. Siegmund, S. Schmelz, S. Dickgiesser, J. Beck, A. Ebenig et al., Locked by Design: A Conformationally Constrained Transglutaminase Tag Enables Efficient Site-Specific Conjugation, Angew. Chem. Int. Ed Engl, 2015.

L. C. Simmons, D. Reilly, L. Klimowski, T. Shantha-raju, G. Meng et al., Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies, J. Immunol. Methods, vol.263, pp.133-147, 2002.

E. M. Sletten and C. R. Bertozzi, Bioorthogonal chemistry: fishing for selectivity in a sea of functionality, Angew. Chem. Int. Ed Engl, vol.48, pp.6974-6998, 2009.

G. P. Smith, Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface, Science, vol.228, pp.1315-1317, 1985.

S. A. Smith and J. E. Crowe, Use of Human Hybridoma Technology To Isolate Human Monoclonal Antibodies, Antibodies for Infectious, pp.141-156, 2015.

E. L. Smith, J. P. Giddens, A. T. Iavarone, K. Godula, L. Wang et al., , 2014.

, Chemoenzymatic Fc Glycosylation via Engineered Aldehyde Tags, Bioconjug. Chem

P. Sondermann and D. E. Szymkowski, Harnessing Fc receptor biology in the design of therapeutic antibodies, Curr. Opin. Immunol, vol.40, pp.78-87, 2016.

P. Sondermann, R. Huber, V. Oosthuizen, J. , and U. , The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex, Nature, vol.406, pp.267-273, 2000.

H. Sonoda, Y. Kumada, T. Katsuda, Y. , and H. , Effects of cytoplasmic and periplasmic chaperones on secretory production of single-chain Fv antibody in Escherichia coli, J. Biosci. Bioeng, vol.111, pp.465-470, 2011.

D. Soriano-del-amo, W. Wang, H. Jiang, C. Besanceney, A. C. Yan et al., Biocompatible Copper(I) Catalysts for in Vivo Imaging of Glycans, J. Am. Chem. Soc, vol.132, pp.16893-16899, 2010.

O. Spadiut, S. Capone, F. Krainer, A. Glieder, and C. Herwig, Microbials for the production of monoclonal antibodies and antibody fragments, Trends Biotechnol, vol.32, pp.54-60, 2014.

G. M. Spiekermann, P. W. Finn, E. S. Ward, J. Dumont, B. L. Dickinson et al., Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung, J. Exp. Med, vol.196, pp.303-310, 2002.

C. Spiess, Q. Zhai, and P. J. Carter, Alternative molecular formats and therapeutic applications for bispecific antibodies, Mol. Immunol, vol.67, pp.95-106, 2015.

B. Spolaore, S. Raboni, A. Ramos-molina, A. Satwekar, N. Damiano et al., Local unfolding is required for the site-specific protein modification by transglutaminase, Biochemistry (Mosc.), vol.51, pp.8679-8689, 2012.

J. B. Stimmel, B. M. Merrill, L. F. Kuyper, C. P. Moxham, J. T. Hutchins et al., Site-specific Conjugation on Serine ? Cysteine Variant Monoclonal Antibodies, J. Biol. Chem, vol.275, pp.30445-30450, 2000.

P. Strop, M. G. Dorywalska, A. Rajpal, D. Shelton, S. Liu et al., , 2012.

, Engineered Polypeptide Conjugates and Methods for Making Thereof Using Transglutaminase, WO patent, 2012059882.

P. Strop, S. Liu, M. Dorywalska, K. Delaria, R. G. Dushin et al., Location Matters: Site of Conjugation Modulates Stability and Pharmacokinetics of Antibody Drug Conjugates, Chem. Biol, vol.20, pp.161-167, 2013.

P. Strop, K. Delaria, D. Foletti, J. M. Witt, A. Hasa-moreno et al., Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading, Nat. Biotechnol, vol.33, pp.694-696, 2015.

F. W. Studier, Protein production by auto-induction in high density shaking cultures, Protein Expr. Purif, vol.41, pp.207-234, 2005.

F. W. Studier and B. A. Moffatt, Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes, J. Mol. Biol, vol.189, pp.113-130, 1986.

Y. Sugimura, K. Yokoyama, N. Nio, M. Maki, and K. Hitomi, Identification of preferred substrate sequences of microbial transglutaminase from Streptomyces mobaraensis using a phage-displayed peptide library, Arch. Biochem. Biophys, vol.477, pp.379-383, 2008.

M. M. Sun, K. S. Beam, C. G. Cerveny, K. J. Hamblett, R. S. Blackmore et al., Reduction-Alkylation Strategies for the Modification of Specific Monoclonal Antibody Disulfides, Bioconjug. Chem, vol.16, pp.1282-1290, 2005.

T. Takazawa, N. Kamiya, H. Ueda, and T. Nagamune, Enzymatic labeling of a single chain variable fragment of an antibody with alkaline phosphatase by microbial transglutaminase, Biotechnol. Bioeng, vol.86, pp.399-404, 2004.

M. H. Tao, R. I. Smith, and S. L. Morrison, Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation, J. Exp. Med, vol.178, pp.661-667, 1993.

M. Terme, S. Pernot, E. Marcheteau, F. Sandoval, N. Benhamouda et al., VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer, Cancer Res, vol.73, pp.539-549, 2013.

D. Ternant, C. Arnoult, M. Pugnière, C. Dhommée, D. Drocourt et al., IgG1 Allotypes Influence the Pharmacokinetics of Therapeutic Monoclonal Antibodies through FcRn Binding, J. Immunol, vol.196, pp.607-613, 2016.
URL : https://hal.archives-ouvertes.fr/hal-02299104

S. Tonegawa, Somatic generation of immune diversity, Biosci. Rep, vol.8, pp.3-26, 1988.

C. W. Tornøe, C. Christensen, and M. Meldal, Peptidotriazoles on solid phase: [1,2,3]-triazoles by regiospecific copper(i)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides, J. Org. Chem, vol.67, pp.3057-3064, 2002.

M. Van-roy, C. Ververken, E. Beirnaert, S. Hoefman, J. Kolkman et al., The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis, Arthritis Res. Ther, vol.17, p.135, 2015.

G. Veggiani and A. Marco, Improved quantitative and qualitative production of single-domain intrabodies mediated by the co-expression of Erv1p sulfhydryl oxidase, Protein Expr. Purif, vol.79, pp.111-114, 2011.

M. Venturi, C. Seifert, and C. Hunte, High level production of functional antibody Fab fragments in an oxidizing bacterial cytoplasm, J. Mol. Biol, vol.315, pp.1-8, 2002.

G. Vidarsson, A. M. Stemerding, N. M. Stapleton, S. E. Spliethoff, H. Janssen et al., FcRn: an IgG receptor on phagocytes with a novel role in phagocytosis, Blood, vol.108, pp.3573-3579, 2006.

D. J. Vugts, A. Vervoort, M. Stigter-van-walsum, G. W. Visser, M. S. Robillard et al., Synthesis of phosphine and antibody-azide probes for in vivo Staudinger ligation in a pretargeted imaging and therapy approach, Bioconjug. Chem, vol.22, pp.2072-2081, 2011.

A. A. Wakankar, M. B. Feeney, J. Rivera, Y. Chen, M. Kim et al., Physicochemical stability of the antibody-drug conjugate Trastuzumab-DM1: changes due to modification and conjugation processes, Bioconjug. Chem, vol.21, pp.1588-1595, 2010.

L. Wang, G. Amphlett, W. A. Blättler, J. M. Lambert, and W. Zhang, Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry, Protein Sci. Publ. Protein Soc, vol.14, pp.2436-2446, 2005.

Y. Wang, Z. Tian, D. Thirumalai, and X. Zhang, Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering, J. Drug Target, vol.22, pp.269-278, 2014.

W. Weng and R. Levy, Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.21, pp.3940-3947, 2003.

A. P. West and P. J. Bjorkman, Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor(,), Biochemistry (Mosc.), vol.39, pp.9698-9708, 2000.

A. F. Williams and A. N. Barclay, The immunoglobulin superfamily--domains for cell surface recognition, Annu. Rev. Immunol, vol.6, pp.381-405, 1988.

G. Winter, A. D. Griffiths, R. E. Hawkins, and H. R. Hoogenboom, Making antibodies by phage display technology, Annu. Rev. Immunol, vol.12, pp.433-455, 1994.

G. Wittig and A. Krebs, Zur Existenz niedergliedriger Cycloalkine, I, Chem. Ber, vol.94, pp.3260-3275, 1961.

L. S. Witus, T. Moore, B. W. Thuronyi, A. P. Esser-kahn, R. A. Scheck et al., Identification of Highly Reactive Sequences For PLP-Mediated Bioconjugation Using a Combinatorial Peptide Library, J. Am. Chem. Soc, vol.132, pp.16812-16817, 2010.

R. Wong, C. Pepper, P. Brennan, D. Nagorsen, S. Man et al., , 2013.

, Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells, Haematologica, vol.98, pp.1930-1938

A. Wörn and A. Plückthun, An intrinsically stable antibody scFv fragment can tolerate the loss of both disulfide bonds and fold correctly, FEBS Lett, vol.427, pp.357-361, 1998.

J. A. Woyach, F. Awan, I. W. Flinn, J. G. Berdeja, E. Wiley et al., A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL, Blood, vol.124, pp.3553-3560, 2014.

H. Wu, Y. Nie, W. D. Huse, and J. D. Watkins, Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues, J. Mol. Biol, vol.294, pp.151-162, 1999.

P. Wu, W. Shui, B. L. Carlson, N. Hu, D. Rabuka et al., Sitespecific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag, Proc. Natl. Acad. Sci, vol.106, pp.3000-3005, 2009.

G. T. Wurz, C. Kao, and M. W. Degregorio, Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential, Ther. Adv. Med. Oncol, vol.8, pp.4-31, 2016.

N. Yamane-ohnuki and M. Satoh, Production of therapeutic antibodies with controlled fucosylation, mAbs, vol.1, pp.230-236, 2009.

Y. A. Yeung, M. K. Leabman, J. S. Marvin, J. Qiu, C. W. Adams et al., Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates, J. Immunol. Baltim. Md, vol.182, pp.7663-7671, 1950.

T. Ying, R. Gong, T. W. Ju, P. Prabakaran, and D. S. Dimitrov, Engineered Fc based antibody domains and fragments as novel scaffolds, Biochim. Biophys. Acta, vol.1844, pp.1977-1982, 2014.

D. York, J. Baker, P. G. Holder, L. C. Jones, P. M. Drake et al., Generating aldehyde-tagged antibodies with high titers and high formylglycine yields by supplementing culture media with copper(II), BMC Biotechnol, vol.16, p.23, 2016.

J. Zalevsky, A. K. Chamberlain, H. M. Horton, S. Karki, I. W. Leung et al., Enhanced antibody half-life improves in vivo activity, Nat. Biotechnol, vol.28, pp.157-159, 2010.

B. M. Zeglis, C. B. Davis, R. Aggeler, H. C. Kang, A. Chen et al., Enzyme-mediated methodology for the site-specific radiolabeling of antibodies based on catalyst-free click chemistry, Bioconjug. Chem, vol.24, pp.1057-1067, 2013.

H. Zhang, Empowering scFv with effector cell functions for improved anticancer therapeutics, 2013.

N. Zhang, L. Liu, C. D. Dumitru, N. R. Cummings, M. Cukan et al., Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study, mAbs, vol.3, pp.289-298, 2011.

Y. Zhou, A. Goenaga, B. D. Harms, H. Zou, J. Lou et al., Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies, Mol. Cancer Ther, vol.11, pp.1467-1476, 2012.

E. S. Zimmerman, T. H. Heibeck, A. Gill, X. Li, C. J. Murray et al., Production of Site-Specific Antibody-Drug Conjugates Using Optimized Non-Natural Amino Acids in a Cell-Free Expression System, Bioconjug. Chem, 2014.